CSL Behring Limited Foreign Taiwan 100 % CSL Behring Biyoterapi llac Dis Ticaret AS Foreign Turkey 100 % CSL Behring UK Limited Foreign UK 100 % CSL Finance Plc Foreign UK 100 % CSL Behring Holdings Limited Foreign UK 100 % Seqirus Holdings UK Limited Foreign UK 100 % Seqirus Limited Foreign UK 100 % Seqirus UK Limited Foreign UK 100 % Seqirus Vaccines Limited Foreign UK 100 % Vifor Pharma UK Limited Foreign UK 100 % CSL Behring LLC Foreign USA 100 % CSL Plasma Puerto Rico LLC Foreign USA (Puerto Rico) 100 % CSL Plasma Inc. Foreign USA 100 % CSL Behring Gene Therapy, Inc. Foreign USA 100 % CSLB Holdings Inc. Foreign USA 100 % Seqirus USA Inc. Foreign USA 100 % Seqirus Inc. Foreign USA 100 % Vifor Pharma, Inc. Foreign USA 100 % CSL Behring MEA FZ-LLC Foreign UAE 100 % Controlled entities (not wholly owned) of CSL Limited:10 Cervax Pty. Limited Australian Australia 74 % Vifor Fresenius Medical Care Renal Pharma België NV Foreign Belgium 55 % Vifor Fresenius Kabi (Beijing) Pharmaceutical Consulting Co. Ltd. Foreign China 55 % Vifor Fresenius Medical Care Renal Pharma France S.A.S. Foreign France 55 % Fresenius Medical Care Nephrologica Deutschland GmbH Foreign Germany 55 % Vifor Fresenius Medical Care Renal Pharma Italia S.r.l. Foreign Italy 55 % Vifor Fresenius Medical Care Renal Pharma Nederland B.V. Foreign Netherlands 55 % Vifor Fresenius Medical Care Renal Pharma España, S.L. Foreign Spain 55 % Vifor Fresenius Medical Care Renal Pharma AG Foreign Switzerland 55 % Vifor Fresenius Medical Care Renal Pharma UK Limited Foreign UK 55 % Consolidated Entity Disclosure Statement 135 For the Year Ended 30 June 2026 10 Represents a participating entity of a joint venture that is consolidated in the Group's consolidated financial information. 135 CSL Limited Annual Report 2025/26
RkJQdWJsaXNoZXIy MjE2NDg3